IN2012DN01708A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01708A IN2012DN01708A IN1708DEN2012A IN2012DN01708A IN 2012DN01708 A IN2012DN01708 A IN 2012DN01708A IN 1708DEN2012 A IN1708DEN2012 A IN 1708DEN2012A IN 2012DN01708 A IN2012DN01708 A IN 2012DN01708A
- Authority
- IN
- India
- Prior art keywords
- tumors
- folate
- ovarian
- methods
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23059509P | 2009-07-31 | 2009-07-31 | |
| US34644410P | 2010-05-19 | 2010-05-19 | |
| US35102210P | 2010-06-03 | 2010-06-03 | |
| PCT/US2010/043992 WO2011014821A1 (en) | 2009-07-31 | 2010-07-30 | Folate-targeted diagnostics and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01708A true IN2012DN01708A (https=) | 2015-06-05 |
Family
ID=43529728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1708DEN2012 IN2012DN01708A (https=) | 2009-07-31 | 2010-07-30 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20120128587A1 (https=) |
| EP (1) | EP2460013A4 (https=) |
| JP (1) | JP2013501224A (https=) |
| KR (1) | KR20120050462A (https=) |
| CN (2) | CN104857534A (https=) |
| AU (1) | AU2010278734A1 (https=) |
| BR (1) | BR112012002064A2 (https=) |
| CA (1) | CA2769754A1 (https=) |
| IL (1) | IL217744A0 (https=) |
| IN (1) | IN2012DN01708A (https=) |
| NZ (1) | NZ598145A (https=) |
| RU (1) | RU2012105641A (https=) |
| WO (1) | WO2011014821A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4464384A3 (en) | 2007-08-17 | 2025-01-08 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| KR20130140033A (ko) | 2010-11-12 | 2013-12-23 | 엔도사이트, 인코포레이티드 | 암을 치료하는 방법들 |
| KR20140022879A (ko) * | 2011-04-12 | 2014-02-25 | 엔도사이트, 인코포레이티드 | 고체 약학 조성물 |
| BR112015011118B1 (pt) | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| US10188738B2 (en) | 2013-10-16 | 2019-01-29 | Université Libre de Bruxelles | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| WO2015077303A1 (en) | 2013-11-19 | 2015-05-28 | Purdue Research Foundation | Patient selection method for inflammation |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| CA2973380A1 (en) * | 2015-01-11 | 2016-07-14 | Endocyte, Inc. | Cancer imaging agent |
| IL237525A (en) | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| WO2018182776A1 (en) * | 2016-03-29 | 2018-10-04 | Endocyte, Inc. | Folate conjugate for use in targeting tumor associated macrophages |
| WO2017192863A1 (en) | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| WO2017205661A1 (en) * | 2016-05-25 | 2017-11-30 | Purdue Research Foundation | Method of treating cancer by targeting myeloid-derived suppressor cells |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CN121337736A (zh) * | 2025-12-16 | 2026-01-16 | 临沂市人民医院 | 多柔比星与免疫调节剂共载脂质体的制备及其协同抗肿瘤用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1592457T3 (da) * | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
| ATE494012T1 (de) * | 2004-12-21 | 2011-01-15 | Nektar Therapeutics | Stabilisierte polymer-thiol-reagenzien |
| RU2007128036A (ru) * | 2004-12-23 | 2009-01-27 | Пердью Рисерч Фаундейшн (Us) | Способ получения изображения позитронно-эмиссионной томографией |
| EP1863816B1 (en) * | 2005-03-16 | 2014-06-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
| ATE460668T1 (de) * | 2005-03-30 | 2010-03-15 | Purdue Research Foundation | Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US20100112039A1 (en) * | 2006-10-25 | 2010-05-06 | Schering Corporation | Methods of treating ovarian cancer |
| BRPI0812970A2 (pt) * | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
-
2010
- 2010-07-30 EP EP10805137A patent/EP2460013A4/en not_active Withdrawn
- 2010-07-30 BR BR112012002064A patent/BR112012002064A2/pt not_active IP Right Cessation
- 2010-07-30 KR KR1020127005358A patent/KR20120050462A/ko not_active Ceased
- 2010-07-30 US US13/388,184 patent/US20120128587A1/en not_active Abandoned
- 2010-07-30 WO PCT/US2010/043992 patent/WO2011014821A1/en not_active Ceased
- 2010-07-30 CA CA2769754A patent/CA2769754A1/en not_active Abandoned
- 2010-07-30 JP JP2012523104A patent/JP2013501224A/ja active Pending
- 2010-07-30 CN CN201510160314.2A patent/CN104857534A/zh active Pending
- 2010-07-30 RU RU2012105641/15A patent/RU2012105641A/ru not_active Application Discontinuation
- 2010-07-30 AU AU2010278734A patent/AU2010278734A1/en not_active Abandoned
- 2010-07-30 CN CN2010800434602A patent/CN102549434A/zh active Pending
- 2010-07-30 NZ NZ598145A patent/NZ598145A/en not_active IP Right Cessation
- 2010-07-30 IN IN1708DEN2012 patent/IN2012DN01708A/en unknown
-
2012
- 2012-01-26 IL IL217744A patent/IL217744A0/en unknown
-
2013
- 2013-03-13 US US13/800,309 patent/US20140140925A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140140925A1 (en) | 2014-05-22 |
| EP2460013A1 (en) | 2012-06-06 |
| US20120128587A1 (en) | 2012-05-24 |
| BR112012002064A2 (pt) | 2017-05-09 |
| JP2013501224A (ja) | 2013-01-10 |
| WO2011014821A1 (en) | 2011-02-03 |
| KR20120050462A (ko) | 2012-05-18 |
| CN102549434A (zh) | 2012-07-04 |
| EP2460013A4 (en) | 2013-04-03 |
| CN104857534A (zh) | 2015-08-26 |
| CA2769754A1 (en) | 2011-02-03 |
| RU2012105641A (ru) | 2013-09-10 |
| NZ598145A (en) | 2014-10-31 |
| IL217744A0 (en) | 2012-03-29 |
| AU2010278734A1 (en) | 2012-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01708A (https=) | ||
| Martin et al. | Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine | |
| Shao et al. | Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer | |
| WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
| MX2010004671A (es) | Seprasa como marcador para cancer. | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| MX347893B (es) | Conjugados de farmaco y anticuerpo humano contra factor de tejido. | |
| MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
| PH12014502507A1 (en) | Anti-angiogenesis therapy for the treatment of breast cancer | |
| PH12014502399A1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
| GB2471588A (en) | Therapeutic peptidomimetic macrocycles | |
| EP3064509A3 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| MX2012001716A (es) | Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf. | |
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| MX2009010439A (es) | Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. | |
| WO2007109347A3 (en) | N-cadherin and ly6 e: targets for cancer diagnosis and therapy | |
| WO2011087709A3 (en) | Eml4-alk translocations in lung cancer | |
| MX2012007940A (es) | Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab. | |
| MA33091B1 (fr) | Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques | |
| WO2010099137A3 (en) | In situ methods for monitoring the emt status of tumor cells in vivo | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| WO2016014799A9 (en) | Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy | |
| WO2014205342A3 (en) | Methods for treatment of ovarian cancer | |
| Alonso-Curbelo et al. | Self-killing of melanoma cells by cytosolic delivery of dsRNA: wiring innate immunity for a coordinated mobilization of endosomes, autophagosomes and the apoptotic machinery in tumor cells |